Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer
BackgroundCastration-resistant prostate cancer (CRPC) has a poor prognosis and requires novel therapeutic approaches. Previously, we discovered that a high dose of human peripheral blood-derived natural killer (PB-NK) cells can have antitumor effects a…